Alignment Healthcare, Inc. (ALHC)

Insider Trading Filed: 2026-04-15

Key Insights

Dawn C. Maroney, the President of Alignment Healthcare, Inc., sold 30,000 shares of the company's common stock on April 15, 2026 at a weighted average price of $20.8733 per share.
The sale represents a small fraction (around 2.8%) of Maroney's total beneficial ownership in the company, which remains at over 1 million shares.
The sale was made pursuant to a pre-arranged Rule 10b5-1 trading plan, indicating it was part of a planned strategy rather than a reaction to a specific event.

Insider Trading Filed: 2026-04-13

Key Insights

The SEC Form 4 filing shows that John E. Kao, the Chief Executive Officer and a Director of Alignment Healthcare, Inc. (ALHC), has been selling a significant number of ALHC shares in recent transactions.
The total number of shares sold by Kao on April 10th and April 13th, 2026 amounts to 298,000 shares, reducing his beneficial ownership in the company.
The sale of shares was executed pursuant to a pre-established trading plan (10b5-1 plan), indicating that the transactions were planned in advance and not based on inside information.

Insider Trading Filed: 2026-04-08

Key Insights

The reporting person, James M. Head, who is the Chief Financial Officer of Alignment Healthcare, Inc., sold 11,100 shares of the company's common stock on April 7, 2026, likely to cover tax withholding obligations related to the vesting of restricted stock units.
The sale was executed at a price of $21.08 per share, and the reporting person still holds 173,495 shares of the company's common stock after the transaction.
This transaction appears to be a routine sale to cover tax obligations and does not represent a discretionary trade by the reporting person.

Insider Trading Filed: 2026-04-08

Key Insights

The CEO, John E. Kao, has sold a significant amount of Alignment Healthcare, Inc. (ALHC) shares, totaling 250,000 shares at weighted average prices of $20.67 and $21.40.
The share sales were part of a pre-arranged trading plan (Rule 10b5-1) that was adopted in November 2025, indicating the transactions were preplanned.
Despite the insider sales, the CEO still maintains a substantial direct ownership of 1,784,868 shares in the company, suggesting he remains committed to the long-term success of Alignment Healthcare.

Insider Trading Filed: 2026-03-23

Key Insights

John E. Kao, the Chief Executive Officer and a Director of Alignment Healthcare, Inc., has reported the sale of 118,000 shares of the company's common stock in a Rule 10b5-1 trading plan.
The reported transaction was executed at a weighted-average price of $17.4783 per share, reducing Kao's direct ownership to 1,784,868 shares, while he retains an indirect beneficial ownership of 2,354,641 shares through the JEK Trust.
Insider selling by a company's CEO can sometimes signal a lack of confidence in the company's future performance, though the use of a pre-planned trading arrangement may indicate that the sale was not based on material non-public information.

Insider Trading Filed: 2026-03-19

Key Insights

Insider John E. Kao, the Chief Executive Officer and a Director of Alignment Healthcare, Inc. (ALHC), sold 73,046 shares of common stock on March 18, 2026 to cover tax withholding obligations related to the vesting of restricted stock units.
The sale was executed at a weighted-average price of $17.84 per share, and Kao still beneficially owns a total of 4,257,509 shares, including 2,472,641 shares held indirectly through the JEK Trust.
This transaction appears to be a routine sale to cover tax obligations and not a discretionary sale, suggesting Kao's continued confidence in the company.

Insider Trading Filed: 2026-03-19

Key Insights

The reporting person, Sebastian Burzacchi, sold 15,361 shares of common stock of Alignment Healthcare, Inc. (ALHC) at a weighted average price of $17.84 per share.
The sale of shares was to cover tax withholding obligations in connection with the vesting of restricted stock units, and not a discretionary trade by the reporting person.
The reporting person still holds 258,630 shares of common stock directly, suggesting continued ownership and commitment to the company.

Insider Trading Filed: 2026-03-19

Key Insights

Hyong (Ken) Kim, the Chief Medical Officer of Alignment Healthcare, Inc., sold 18,404 shares of the company's common stock on March 18, 2026, likely to cover tax withholding obligations related to the vesting of restricted stock units.
The shares were sold at a weighted-average price of $17.84, which is within the reported price range of $17.40 to $18.24 per share.
Following the transaction, Kim's beneficial ownership of Alignment Healthcare's common stock decreased to 367,701 shares, which remains a significant holding.

Insider Trading Filed: 2026-03-19

Key Insights

Christopher J. Joyce, the Chief Legal and Administrative Officer, sold 25,125 shares of Alignment Healthcare, Inc. (ALHC) on March 18, 2026 at a weighted average price of $17.84 per share.
The sale was to cover tax withholding obligations in connection with the vesting of restricted stock units, and not a discretionary trade.
Following the sale, Joyce continues to hold 323,464 shares of ALHC directly, indicating he still maintains a significant stake in the company.

Insider Trading Filed: 2026-03-19

Key Insights

Dawn C. Maroney, the President of Alignment Healthcare, Inc., sold 36,749 shares of the company's common stock on March 18, 2026, likely to cover tax withholding obligations related to the vesting of restricted stock units.
The sale was executed at a weighted-average price of $17.84 per share, within a price range of $17.40 to $18.24.
Following the reported transaction, Maroney continues to hold 1,058,813 shares of Alignment Healthcare, Inc. common stock, representing a significant insider ownership stake.

Insider Trading Filed: 2026-03-19

Key Insights

Insider Robert L. Scavo, the Chief Information Officer, sold 11,285 shares of Alignment Healthcare, Inc. (ALHC) stock on March 18, 2026 at a weighted-average price of $17.84.
The sale was made to cover tax withholding obligations related to the vesting of restricted stock units, and does not represent a discretionary trade.
Scavo still holds a significant 487,685 shares of ALHC stock, indicating he maintains a substantial stake in the company.

Insider Trading Filed: 2026-03-19

Key Insights

The reporting person, Andreas P. Wagner, sold a total of 23,602 shares of Alignment Healthcare, Inc. (ALHC) common stock over two trading days, March 18 and 19, 2026.
The sale of shares appears to be related to the vesting of restricted stock units and the need to cover tax withholding obligations, as stated in the filing.
The reporting person continues to hold a significant position of 148,628 shares, suggesting they remain invested in the company.

Insider Trading Filed: 2026-01-16

Key Insights

The reported insider sale of 30,000 shares by President Dawn Maroney at an average price of $22.48 represents a significant portion of her holdings, which could signal potential concerns.
The sale was executed under a previously adopted 10b5-1 trading plan, providing some reassurance that it was not an opportunistic trade based on inside information.
Investors should monitor any further insider selling activity and consider its potential implications for the company's outlook and stock performance.

Insider Trading Filed: 2026-01-14

Key Insights

Insider John E. Kao, the CEO of Alignment Healthcare, Inc., has sold a significant portion of his direct equity holdings in the company, transferring 665,915 shares to a trust of which he is the trustee.
Kao's stock sales were executed pursuant to a pre-arranged 10b5-1 trading plan, indicating a planned and structured approach to his share dispositions.
The reported sales were made at weighted-average prices of $21.10 and $21.57 per share, suggesting Kao may have been taking advantage of recent stock price appreciation.

Current Report Filed: 2026-01-12

Key Insights

Alignment Healthcare, Inc. (ALHC) expects to have approximately 275,300 Health Plan Members as of January 1, 2026, representing 31% year-over-year growth.
The company expects to have 290,000 to 296,000 Health Plan Members as of December 31, 2026, representing approximately 24% to 27% growth relative to the midpoint of the company's latest guidance.
Alignment Healthcare is reaffirming its full-year 2025 guidance ranges for Health Plan Membership, Revenue, Adjusted Gross Profit, and Adjusted EBITDA.

Insider Trading Filed: 2025-12-30

Key Insights

The reporting person, Christopher J. Joyce, who is the Chief Legal and Administrative Officer of Alignment Healthcare, Inc., sold 16,187 shares of the company's common stock on December 29, 2025, likely to cover tax withholding obligations related to the vesting of performance share units.
The reported transactions were not discretionary trades by the reporting person, but rather required sales to satisfy tax obligations, indicating the sales were routine in nature.
The reporting person continues to hold a significant number of shares (307,699) following the reported transactions, suggesting continued alignment with the company's long-term interests.

Insider Trading Filed: 2025-12-30

Key Insights

The reporting person, Robert L. Scavo, who is the Chief Information Officer of Alignment Healthcare, Inc., sold a total of 69,541 shares of the company's common stock on December 29, 2025.
The sale of shares was to cover tax withholding obligations in connection with the vesting of performance share units, and not a discretionary trade by the reporting person.
The reported weighted-average prices for the shares sold were $18.7056 and $19.3818, indicating the reporting person may have sold shares at different price points within the reported ranges.

Insider Trading Filed: 2025-12-30

Key Insights

The reporting person, Hyong (Ken) Kim, who is the Chief Medical Officer of Alignment Healthcare, Inc., sold a total of 12,694 shares of the company's common stock on December 29, 2025 to cover tax withholding obligations related to the vesting of performance share units.
The sales were executed at weighted-average prices of $18.7056 and $19.3818 per share, respectively, representing a total transaction value of approximately $239,000.
The reporting person continues to hold a significant ownership stake of 349,639 shares, indicating ongoing commitment to the company.

Insider Trading Filed: 2025-12-30

Key Insights

The CEO, John E. Kao, sold a significant number of shares (572,437 and 33,211) on December 29, 2025, likely to cover tax withholding obligations related to the vesting of performance share units.
The shares were sold at weighted-average prices of $18.7056 and $19.3818, which provides insight into the stock's trading range around that time.
The CEO still holds a substantial indirect ownership stake of 2,346,726 shares through the JEK Trust, suggesting he maintains a significant long-term interest in the company.

Insider Trading Filed: 2025-12-30

Key Insights

The reporting person, Dawn C. Maroney, sold a significant number of shares (282,070 shares) on 12/29/2025, potentially signaling an insider selling activity.
The reported transactions were to cover tax withholding obligations in connection with the vesting of performance share units, rather than discretionary trades, which may provide a different context for the selling activity.
The reporting person still holds a substantial number of shares (1,385,167) following the reported transactions, suggesting they maintain a significant ownership stake in the company.

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Important Information